Clinical and Radiologic Improvement Following Tocilizumab Administration in Patients With SARS-CoV-2

Cytokine release syndrome and acute respiratory distress syndrome are the major complications of coronavirus disease 2019 (COVID-19) and tocilizumab has shown efficacy in this setting. We report on 2 severely ill patients with COVID-19 treated with tocilizumab within 7 to 10 days of onset of symptoms. Tocilizumab markedly improved their clinical condition and was associated with regression of abnormalities on chest computed tomography within 1 week of tocilizumab administration.